WO2004009072A3 - Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies - Google Patents

Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies Download PDF

Info

Publication number
WO2004009072A3
WO2004009072A3 PCT/US2003/022914 US0322914W WO2004009072A3 WO 2004009072 A3 WO2004009072 A3 WO 2004009072A3 US 0322914 W US0322914 W US 0322914W WO 2004009072 A3 WO2004009072 A3 WO 2004009072A3
Authority
WO
WIPO (PCT)
Prior art keywords
related compounds
compounds
angiogenic therapies
tetrapropylammonium tetrathiomolybdate
tetrathiomolybdate
Prior art date
Application number
PCT/US2003/022914
Other languages
French (fr)
Other versions
WO2004009072A2 (en
WO2004009072B1 (en
Inventor
George J Brewer
Sofia D Merajver
Dimitri Coucouvanis
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200500244A priority Critical patent/EA008683B1/en
Application filed by Univ Michigan filed Critical Univ Michigan
Priority to CA002493341A priority patent/CA2493341A1/en
Priority to EP03765921A priority patent/EP1539131A4/en
Priority to BR0312845-8A priority patent/BR0312845A/en
Priority to JP2004523295A priority patent/JP2005538093A/en
Priority to MXPA05000875A priority patent/MXPA05000875A/en
Priority to NZ537896A priority patent/NZ537896A/en
Priority to AU2003261222A priority patent/AU2003261222B2/en
Publication of WO2004009072A2 publication Critical patent/WO2004009072A2/en
Publication of WO2004009072A3 publication Critical patent/WO2004009072A3/en
Publication of WO2004009072B1 publication Critical patent/WO2004009072B1/en
Priority to IL16638505A priority patent/IL166385A0/en
Priority to NO20050902A priority patent/NO20050902L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.
PCT/US2003/022914 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies WO2004009072A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MXPA05000875A MXPA05000875A (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies.
CA002493341A CA2493341A1 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
EP03765921A EP1539131A4 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
BR0312845-8A BR0312845A (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for antiangiogenic therapies
JP2004523295A JP2005538093A (en) 2002-07-23 2003-07-23 Tetrapolyammonium tetrathiomolybdate and related compounds for anti-angiogenic therapy
EA200500244A EA008683B1 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
NZ537896A NZ537896A (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
AU2003261222A AU2003261222B2 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IL16638505A IL166385A0 (en) 2002-07-23 2005-01-20 Tetrapropylammonium terathiomolybodate and relatedcompounds for anti-angiogenic therapies
NO20050902A NO20050902L (en) 2002-07-23 2005-02-18 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39780402P 2002-07-23 2002-07-23
US60/397,804 2002-07-23

Publications (3)

Publication Number Publication Date
WO2004009072A2 WO2004009072A2 (en) 2004-01-29
WO2004009072A3 true WO2004009072A3 (en) 2004-04-08
WO2004009072B1 WO2004009072B1 (en) 2004-07-08

Family

ID=30771119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022914 WO2004009072A2 (en) 2002-07-23 2003-07-23 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Country Status (16)

Country Link
US (1) US7888389B2 (en)
EP (1) EP1539131A4 (en)
JP (1) JP2005538093A (en)
KR (1) KR20050025976A (en)
CN (1) CN1688303A (en)
AU (1) AU2003261222B2 (en)
BR (1) BR0312845A (en)
CA (1) CA2493341A1 (en)
EA (1) EA008683B1 (en)
GE (1) GEP20074270B (en)
IL (1) IL166385A0 (en)
MX (1) MXPA05000875A (en)
NO (1) NO20050902L (en)
NZ (1) NZ537896A (en)
WO (1) WO2004009072A2 (en)
ZA (1) ZA200501162B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
EP1115389B1 (en) * 1998-09-25 2014-03-12 PhilERA New Zealand Limited Fructosamine oxidase: antagonists and inhibitors
CN1649577A (en) * 2002-03-08 2005-08-03 普罗特米克斯公司 Preventing and/or treating cardiovascular disease and/or associated heart failure
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
KR20050025976A (en) 2002-07-23 2005-03-14 더 리젠츠 오브 더 유니버시티 오브 미시건 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
RU2002128364A (en) * 2002-10-23 2004-04-27 Институт нефтехимического синтеза РАН им. А.В. Топчиева METHOD FOR PRODUCING ADDITIVE TO LUBRICANTS (OPTIONS)
PL218366B1 (en) * 2003-05-27 2014-11-28 Attenuon Thiotungstate analogues and uses thereof
WO2005082382A1 (en) * 2004-02-23 2005-09-09 Attenuon Llc Formulations of thiomolybdate or thiotungstate compounds and uses thereof
AU2005217623A1 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
CA2577634C (en) * 2004-07-19 2015-07-07 Protemix Corporation Limited Synthesis of triethylenetetramines
WO2006044779A1 (en) * 2004-10-14 2006-04-27 Northwestern University Detection and treatment of renal cancer
WO2008103421A1 (en) * 2007-02-21 2008-08-28 Ssv Therapeutics, Inc. Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
WO2009009622A2 (en) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US20100312139A1 (en) * 2009-06-04 2010-12-09 Board Of Regents Of The University Of Texas System Method for Identifying Mammals at Risk for Elevated intracranial Pressure
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
WO2016126860A1 (en) 2015-02-03 2016-08-11 Kadmon Pharmaceuticals, Llc Stable trientine formulations
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
JP2023549037A (en) 2020-10-07 2023-11-22 シーティーアイ バスキュラー アーゲー Devices and related methods convertible into bioactive forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604278A (en) * 1985-05-17 1986-08-05 Gte Products Corporation Production of ammonium tetrathiomolybdate

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4343746A (en) 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4762705A (en) 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4952607A (en) 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US4430443A (en) * 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
US4766226A (en) 1984-02-01 1988-08-23 Smithkline Beckman Corporation Antitumor pharmaceutical compositions and methods for treating tumors employing α,ω-bis(disubstitutedphosphino)hydrocarbon derivatives or [α, ω-bis(disubstitutedphosphino)hydrocarbon] di
EP0226591B1 (en) 1984-12-18 1992-09-23 Clark Pharmaceutical Development, Ltd. Anti-tumor compositions containing the reaction product of a cytotoxic aldehyde with penicillamine and their use for the manufacture of medicaments
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US5385933A (en) 1989-02-27 1995-01-31 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof
US5100885A (en) 1989-08-01 1992-03-31 Johnson Matthey, Inc. Copper radiosensitizers
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
MX172248B (en) 1989-12-20 1993-12-09 Univ Mexico PROCEDURE FOR THE OBTAINING OF NEW MIXED COPPER AMINO ACID COMPLEXES BASED ON FENYLATED PHENANTROLINS AS ANTI-CANCER AGENTS
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1994000118A1 (en) 1992-06-19 1994-01-06 The University Of Toledo Production and use of imines of porphyrins
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
AU701843B2 (en) 1995-03-14 1999-02-04 Siemens Aktiengesellschaft Removable precision dosating unit for ultrasonic atomizer device
NZ304009A (en) 1995-03-14 1999-02-25 Siemens Ag Ultrasonic atomizer device with a removable precision dosating unit
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
DE69904203T2 (en) 1998-09-04 2003-08-14 Univ Michigan Ann Arbor THIOMOLYBDATE ASSOCIATED WITH AT LEAST ONE CARBOHYDRATE, AND ITS USE FOR THE PREVENTION AND TREATMENT OF DISEASES, CHARACTERIZED BY ANALMAL VASCULARIZATION, E.g. CANCER, "DAMP" MACRO DEGENERATION, RHEUMATOIDE ARTHRITIS
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
JP2005504060A (en) * 2001-08-24 2005-02-10 メイン・メデイカル・センター・リサーチ・インステイテユート Copper-dependent non-traditional proinflammatory cytokine transport and related methods, compositions and kits
CA2490541A1 (en) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
KR20050025976A (en) 2002-07-23 2005-03-14 더 리젠츠 오브 더 유니버시티 오브 미시건 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604278A (en) * 1985-05-17 1986-08-05 Gte Products Corporation Production of ammonium tetrathiomolybdate

Also Published As

Publication number Publication date
CN1688303A (en) 2005-10-26
GEP20074270B (en) 2007-12-25
ZA200501162B (en) 2005-09-05
NZ537896A (en) 2007-12-21
US7888389B2 (en) 2011-02-15
EP1539131A2 (en) 2005-06-15
US20040259945A1 (en) 2004-12-23
EA200500244A1 (en) 2005-12-29
WO2004009072A2 (en) 2004-01-29
KR20050025976A (en) 2005-03-14
JP2005538093A (en) 2005-12-15
AU2003261222B2 (en) 2009-07-09
EA008683B1 (en) 2007-06-29
WO2004009072B1 (en) 2004-07-08
AU2003261222A1 (en) 2004-02-09
MXPA05000875A (en) 2005-09-30
CA2493341A1 (en) 2004-01-29
EP1539131A4 (en) 2009-07-08
NO20050902L (en) 2005-04-19
BR0312845A (en) 2005-06-07
IL166385A0 (en) 2006-01-16

Similar Documents

Publication Publication Date Title
WO2004009072A3 (en) Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2007011962A3 (en) Treatment of cancer
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2004103960A3 (en) Compounds and uses thereof
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006034154A3 (en) Salts of 5-azacytidine
WO2006089150A3 (en) Antiangiogenic agents with aldesleukin
WO2006037024A3 (en) Salts of decitabine
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2006098969A3 (en) Quinazolinone t-type calcium channel antagonists
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040211

WWE Wipo information: entry into national phase

Ref document number: 2003261222

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2493341

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004523295

Country of ref document: JP

Ref document number: 1-2005-500141

Country of ref document: PH

Ref document number: PA/a/2005/000875

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057001226

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 238/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 537896

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003765921

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/01162

Country of ref document: ZA

Ref document number: 200501162

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200500244

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 8654

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 2003820746X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057001226

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003765921

Country of ref document: EP